fentanyl has been researched along with Pain, Breakthrough in 162 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rapid-acting fentanyl formulations are superior to oral morphine (OM) syrup in controlling breakthrough pain among patients with cancer, but they are expensive and unavailable in many countries." | 9.69 | Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial. ( Thantiprechapong, T; Tilagul, T; Vasikasin, V, 2023) |
| "The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients." | 9.41 | Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Akbari, ME; Delshad, MH; Golmakani, E; Hashemi, M; Shadnoush, M; Zali, A, 2021) |
| " Intranasal fentanyl 100 µg or 200 µg was used to manage breakthrough pain on the first and third postoperative mornings in a randomised order." | 9.41 | Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery. ( Anderson, BJ; Hakomäki, H; Kokki, H; Kokki, M; Laakso, M; Ranta, VP; Rinne, V; Valtola, A, 2021) |
| "Oral morphine is frequently used for breakthrough pain but the oral route is not always available and absorption is slow." | 9.41 | Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER). ( Harrop, E; Howard, RF; Jamieson, L; Johnson, M; Liossi, C; Mott, C; Oulton, K; Skene, SS; Wong, IC, 2021) |
| "0625% with fentanyl 2 μg/mL at 12 mL/h, a patient-administered bolus of 5 mL at lockout 6-10 min and a maximum of four boluses per hour, and experiencing breakthrough pain ≥5/10, were randomized to receive a 10 mL bolus containing 12." | 9.34 | Comparative efficacy of epidural clonidine versus epidural fentanyl for treating breakthrough pain during labor: a randomized double-blind clinical trial. ( Goodman, S; Landau, R; Lavin, T; Lee, A; Menon, P; Smiley, R, 2020) |
| "Fentanyl buccal soluble film (FBSF), a new formulation of fentanyl, is developed for the treatment of breakthrough pain (BTP) in opioid-tolerant patients with cancer." | 9.30 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. ( Chang, YF; Chao, TC; Chao, TY; Chiou, TJ; Huang, JS; Wang, CH, 2019) |
| "The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP)." | 9.22 | Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. ( Brownlow, RC; Bull, J; Minkowitz, H; Parikh, N; Rauck, R, 2016) |
| "To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP)." | 9.22 | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. ( Alberts, DS; Parikh, N; Rauck, RL; Smith, CC, 2016) |
| "Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP)." | 9.22 | Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. ( Adile, C; Aielli, F; Casuccio, A; Costanzi, A; Mercadante, S, 2016) |
| " The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment." | 9.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. ( Gomyo, I; Katakami, N; Ohta, E; Okada, M; Shimoyama, M; Shimoyama, N; Yukitoshi, N, 2015) |
| "Rapid analgesic onset opioids, particularly fentanyl buccal tablet, is preferable for managing breakthrough pain." | 9.20 | Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c ( Adachi, I; Eguchi, K; Goto, F; Matoba, M; Shima, Y; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2015) |
| "The aims of this study were to explore the efficacy of intranasal fentanyl spray* (INFS) 400 μg to evaluate 12-week tolerability of the nasal mucosa and to explore safety data for all dose strengths of INFS in patients with cancer-related breakthrough pain (BTP)." | 9.20 | Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. ( Eeg, M; Jaatun, E; Kaasa, S; Kvitberg, M; Popper, L; Thronæs, M, 2015) |
| " We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 9.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
| "To investigate the long-term use of fentanyl pectin nasal spray (FPNS) for the treatment of breakthrough pain in cancer (BTPc) in patients receiving regular opioid therapy." | 9.19 | A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. ( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014) |
| "Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients." | 9.19 | A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. ( Bullier, F; Fricova, J; Harabisova, S; Novotna, S; Richterova, E; Trinquet, F; Valentova, K, 2014) |
| "Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain." | 9.19 | Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. ( Narayana, A; Passik, SD; Yang, R, 2014) |
| "Evaluate analgesic efficacy, functional benefit, and patient satisfaction with fentanyl buccal tablet vs immediate-release oxycodone for breakthrough pain (BTP)." | 9.17 | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase ( Earl, CQ; Narayana, A; Slevin, KA; Webster, LR; Yang, R, 2013) |
| "The aim of this study was to evaluate the effectiveness and safety of sublingual fentanyl oral disintegrating tablets (sublingual fentanyl ODT) for the treatment of breakthrough pain (BTP), cancer or non-cancer related, in terms of relief of pain intensity, adverse events (AEs) and patient satisfaction, and to further examine the clinical and epidemiological profile of patients with BTP in a clinical setting." | 9.17 | Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. ( Aberasturi, T; Arilla, M; Coma, J; De Sanctis, V; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Lombán, E; Moya, J; Ribera, H; Rodelas, F; Salazar, R; Sintes, D; Tomás, A; Vargas, I; Vázquez, JM, 2013) |
| "Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing." | 9.16 | Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. ( Fang, WX; Li, F; Sima, L; Wu, XM, 2012) |
| "Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to ≥60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 μg." | 8.91 | Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. ( Mercadante, S, 2015) |
| "The development of intranasal fentanyl (INFS) aimed for a rapid treatment of breakthrough pain (BTP) in cancer patients." | 8.88 | Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. ( Facius, A; Kaessner, N; Lahu, G; Nave, R; Roepcke, S, 2012) |
| "The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain." | 8.87 | Fentanyl for breakthrough pain: a systematic review. ( Davis, MP, 2011) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 8.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP)." | 8.02 | The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. ( Bonetti, A; Fiorica, F; Franceschini, G; Giuliani, J; Sacchetto, A; Vaccari, F, 2021) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 7.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 7.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 7.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| "The aim of this study was to prospectively assess the efficacy and safety of low doses of sublingual fentanyl (SLF) for the treatment of breakthrough pain (BTP) in cancer patients in patients who were receiving low opioid doses for background analgesia." | 7.85 | The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. ( Adile, C; Aielli, F; Casuccio, A; Cuomo, A; Marinangeli, F; Mercadante, S, 2017) |
| "A retrospective analysis was conduct on HNC patients during RT ± ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals." | 7.85 | Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. ( Albanese, S; Alongi, F; Fersino, S; Fiorentino, A; Giaj-Levra, N; Gori, S; Mazzola, R; Ricchetti, F; Tebano, U, 2017) |
| "Data from opioid-tolerant patients participating in clinical studies of fentanyl buccal tablet (FBT) for breakthrough pain (up to 18 months of clinical study case-report forms) were retrospectively reviewed and coded for abuse, overdose, and aberrant behavior." | 7.77 | Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. ( Golsorkhi, A; Messina, J; Passik, SD; Xie, F, 2011) |
| " Adverse events were somnolence and other events associated with opioids were mostly mild or moderate." | 6.79 | A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. ( Adachi, I; Eguchi, K; Goto, F; Hamada, S; Kosugi, T; Kunikane, H; Matoba, M; Shima, Y; Shinozaki, K; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2014) |
| "Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min." | 6.79 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. ( España Ximénez de Enciso, I; García Velasco, P; Muñoz Garrido, JC; Velázquez Clavarana, L; Velázquez Rivera, I, 2014) |
| "However, the treatment of breakthrough pain should be adjusted to suit specific patient requirements." | 6.61 | The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. ( Brząkała, J; Leppert, W, 2019) |
| " Furthermore, it is a reasonably safe treatment, causing generally mild adverse events not leading to treatment discontinuation." | 6.52 | Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. ( Escobar, Y; Moya, J; Murillo, M; Rogríguez, D; Urrutia, G, 2015) |
| "Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life." | 6.49 | Fentanyl for the treatment of tumor-related breakthrough pain. ( Bornemann-Cimenti, H; Sandner-Kiesling, A; Szilagyi, IS; Wejbora, M, 2013) |
| " placebo in the first 30 minutes after dosing (FBT provided an 83% probability of superior pain relief, ODT 66%, and OTFC 73% vs." | 6.49 | Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. ( Bennett, MI; Fullarton, JR; Jandhyala, R, 2013) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain." | 6.48 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. ( Mercadante, S, 2012) |
| " Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results." | 6.47 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. ( Elsner, F; Porta-Sales, J; Tagarro, I; Zeppetella, G, 2011) |
| "Rapid-acting fentanyl formulations are superior to oral morphine (OM) syrup in controlling breakthrough pain among patients with cancer, but they are expensive and unavailable in many countries." | 5.69 | Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial. ( Thantiprechapong, T; Tilagul, T; Vasikasin, V, 2023) |
| "Adverse drug reactions were registered in 3%." | 5.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| "No published studies have looked at the dosing and use of rapid onset fentanyl preparations in children." | 5.46 | The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. ( Anderson, AK; Burke, K; Coombes, L, 2017) |
| "Fentanyl has a strong first pass effect when administered orally and resorbed enterally, however it is well suited for transmucosal administration, e." | 5.46 | [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. ( Überall, MA, 2017) |
| "The pharmacokinetics of the sublingual fentanyl orally disintegrating tablet appear to be negatively affected by the presence of salivary gland hypofunction, although the moistening of the oral cavity before dosing results in a pharmacokinetic profile similar to that seen with the giving of pilocarpine hydrochloride." | 5.43 | The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. ( Buchanan, A; Davies, A; Mundin, G; Vriens, J; Waghorn, M; Webber, K, 2016) |
| "The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients." | 5.41 | Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Akbari, ME; Delshad, MH; Golmakani, E; Hashemi, M; Shadnoush, M; Zali, A, 2021) |
| " Intranasal fentanyl 100 µg or 200 µg was used to manage breakthrough pain on the first and third postoperative mornings in a randomised order." | 5.41 | Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery. ( Anderson, BJ; Hakomäki, H; Kokki, H; Kokki, M; Laakso, M; Ranta, VP; Rinne, V; Valtola, A, 2021) |
| "Oral morphine is frequently used for breakthrough pain but the oral route is not always available and absorption is slow." | 5.41 | Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER). ( Harrop, E; Howard, RF; Jamieson, L; Johnson, M; Liossi, C; Mott, C; Oulton, K; Skene, SS; Wong, IC, 2021) |
| "0625% with fentanyl 2 μg/mL at 12 mL/h, a patient-administered bolus of 5 mL at lockout 6-10 min and a maximum of four boluses per hour, and experiencing breakthrough pain ≥5/10, were randomized to receive a 10 mL bolus containing 12." | 5.34 | Comparative efficacy of epidural clonidine versus epidural fentanyl for treating breakthrough pain during labor: a randomized double-blind clinical trial. ( Goodman, S; Landau, R; Lavin, T; Lee, A; Menon, P; Smiley, R, 2020) |
| "Fentanyl buccal soluble film (FBSF), a new formulation of fentanyl, is developed for the treatment of breakthrough pain (BTP) in opioid-tolerant patients with cancer." | 5.30 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. ( Chang, YF; Chao, TC; Chao, TY; Chiou, TJ; Huang, JS; Wang, CH, 2019) |
| " This open-label, multicenter, noncomparative study aimed to assess the efficacy and safety of proportional doses of fentanyl buccal soluble film (FBSF) in patients with breakthrough cancer pain." | 5.27 | Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study. ( Chiang, WY; Chiou, JF; Hu, MH; Huang, MY; Lai, YL; Su, WH; Wu, SC; Yen, TY, 2018) |
| " The string was "rapid onset opioids" or "transmucosal fentanyl" and "breakthrough cancer pain"." | 5.22 | Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment. ( Armignacco, A; Carpenedo, R; Cascella, M; Chinè, E; Coluccia, S; Crispo, A; Cuomo, A; Cutugno, F; Forte, CA; Franceschini, G; Gennaro, PD; Migliaccio, L; Monaco, F; Natoli, S; Nocerino, D; Picerno, P; Tafuri, M; Tracey, MC; Vittori, A, 2022) |
| "The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP)." | 5.22 | Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. ( Brownlow, RC; Bull, J; Minkowitz, H; Parikh, N; Rauck, R, 2016) |
| "To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP)." | 5.22 | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. ( Alberts, DS; Parikh, N; Rauck, RL; Smith, CC, 2016) |
| "Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP)." | 5.22 | Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. ( Adile, C; Aielli, F; Casuccio, A; Costanzi, A; Mercadante, S, 2016) |
| " The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment." | 5.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. ( Gomyo, I; Katakami, N; Ohta, E; Okada, M; Shimoyama, M; Shimoyama, N; Yukitoshi, N, 2015) |
| " The doses of sublingual fentanyl to treat breakthrough pain were determined from rescue morphine doses by use of conversion ratios." | 5.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. ( Gomyo, I; Higuchi, H; Kojima, K; Ohta, E; Shimoyama, M; Shimoyama, N; Teramoto, O; Yukitoshi, N, 2015) |
| "Rapid analgesic onset opioids, particularly fentanyl buccal tablet, is preferable for managing breakthrough pain." | 5.20 | Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c ( Adachi, I; Eguchi, K; Goto, F; Matoba, M; Shima, Y; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2015) |
| "The aims of this study were to explore the efficacy of intranasal fentanyl spray* (INFS) 400 μg to evaluate 12-week tolerability of the nasal mucosa and to explore safety data for all dose strengths of INFS in patients with cancer-related breakthrough pain (BTP)." | 5.20 | Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. ( Eeg, M; Jaatun, E; Kaasa, S; Kvitberg, M; Popper, L; Thronæs, M, 2015) |
| " We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 5.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
| "To investigate the long-term use of fentanyl pectin nasal spray (FPNS) for the treatment of breakthrough pain in cancer (BTPc) in patients receiving regular opioid therapy." | 5.19 | A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. ( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014) |
| "Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients." | 5.19 | A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. ( Bullier, F; Fricova, J; Harabisova, S; Novotna, S; Richterova, E; Trinquet, F; Valentova, K, 2014) |
| "The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen." | 5.19 | Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. ( Adile, C; Casuccio, A; Mercadante, S; Prestia, G, 2014) |
| "Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain." | 5.19 | Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain. ( Narayana, A; Passik, SD; Yang, R, 2014) |
| "Intranasal Fentanyl Spray (INFS) was developed for the treatment of breakthrough pain (BTP) in cancer patients using a new route of administration." | 5.17 | An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. ( Baumann, S; Facius, A; Hartmann, L; Nave, R; Plock, N, 2013) |
| "Evaluate analgesic efficacy, functional benefit, and patient satisfaction with fentanyl buccal tablet vs immediate-release oxycodone for breakthrough pain (BTP)." | 5.17 | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase ( Earl, CQ; Narayana, A; Slevin, KA; Webster, LR; Yang, R, 2013) |
| "The aim of this study was to evaluate the effectiveness and safety of sublingual fentanyl oral disintegrating tablets (sublingual fentanyl ODT) for the treatment of breakthrough pain (BTP), cancer or non-cancer related, in terms of relief of pain intensity, adverse events (AEs) and patient satisfaction, and to further examine the clinical and epidemiological profile of patients with BTP in a clinical setting." | 5.17 | Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. ( Aberasturi, T; Arilla, M; Coma, J; De Sanctis, V; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Lombán, E; Moya, J; Ribera, H; Rodelas, F; Salazar, R; Sintes, D; Tomás, A; Vargas, I; Vázquez, JM, 2013) |
| "Effective labour analgesia lasting up to 120 minutes was observed in the fentanyl-bupivacaine group but with high incidence of breakthrough pain." | 5.17 | A COMPARATIVE STUDY ON THE EFFICACY OF TWO REGIMENS OF SINGLE- SHOT SPINAL BLOCK FOR PAIN RELIEF IN WOMEN PRESENTING IN ESTABLISHED LABOUR. ( Chokwe, TM; Ogutu, O; Olang, PO; Tshibuyl, PN, 2013) |
| "Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing." | 5.16 | Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. ( Fang, WX; Li, F; Sima, L; Wu, XM, 2012) |
| "Data were derived from 2 clinical trials (Study 1, n=131; Study 2, n=139) of fentanyl sublingual tablet in patients with cancer-associated breakthrough pain (BTP)." | 5.16 | Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies. ( Hassman, D; Howell, J; Nalamachu, SR; Rauck, RL; Wallace, MS, 2012) |
| " Fentanyl is a lipophilic opioid commonly proposed for intranasal use among pediatric patients, but no studies have been conducted yet about intranasal use of other available opioids for management of pediatric cancer pain." | 5.01 | Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies. ( Attinà, G; Capozza, MA; Mastrangelo, S; Maurizi, P; Ruggiero, A; Triarico, S, 2019) |
| " A group of experts nominated by the 3 French Societies involved in the treatment of cancer pain (AFSOS, SFAP, SFETD), established new guidelines ratios for morphine switching and/or changing of route of administration, in patients for whom either pain was not adequatly managed or adverse effects were unbearable." | 4.98 | [Opioid switch and change of route of administration in cancer patients treated by morphine]. ( Ammar, D; Baron, L; Chvetzoff, G; Collin, E; Delorme, C; Delorme, T; Faure, S; Filbet, M; Hubault, P; Jovenin, N; Krakowski, I; Magnet, M; Michenot, N; Minello, C; Poulain, P; Rostaing, S, 2018) |
| "Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to ≥60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 μg." | 4.91 | Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. ( Mercadante, S, 2015) |
| "The original review included four studies (393 participants), all concerned with the use of oral transmucosal fentanyl citrate (OTFC) in the management of breakthrough pain." | 4.89 | Opioids for the management of breakthrough pain in cancer patients. ( Davies, AN; Zeppetella, G, 2013) |
| "Fentanyl buccal tablet (FBT) is indicated for the treatment of breakthrough pain in patients who are already receiving and are tolerant to opioid therapy for underlying, persistent cancer pain." | 4.88 | Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ( Darwish, M; Xie, F, 2012) |
| "The development of intranasal fentanyl (INFS) aimed for a rapid treatment of breakthrough pain (BTP) in cancer patients." | 4.88 | Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. ( Facius, A; Kaessner, N; Lahu, G; Nave, R; Roepcke, S, 2012) |
| "The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain." | 4.87 | Fentanyl for breakthrough pain: a systematic review. ( Davis, MP, 2011) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 4.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP)." | 4.02 | The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. ( Bonetti, A; Fiorica, F; Franceschini, G; Giuliani, J; Sacchetto, A; Vaccari, F, 2021) |
| "Fentanyl buccal tablet (FBT), a potent opioid, was approved in Canada in 2013 for breakthrough pain in opioid-tolerant adult cancer patients." | 3.96 | Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance. ( Bergamasco, A; Castilloux, AM; Kaplan, S; Moride, Y; Sergerie, M, 2020) |
| "Immediate-release fentanyl is indicated in the treatment of breakthrough pain in cancer patients who already receive opioids as background chronic analgesia." | 3.96 | [Comparison of hospital consumption of immediate-release fentanyl: use or abuse?] ( Arrieta Loitegui, M; Caro Teller, JM; Ferrari Piquero, JM; Rosas Espinoza, C, 2020) |
| "Oral transmucosal fentanyl has been indicated for the management of breakthrough pain in patients with cancer." | 3.96 | [A Case Report of Impaired Consciousness in a Patient after Receiving the Fourth Dose of Fentanyl Sublingual Tablet]. ( Kono, T; Satomi, M, 2020) |
| "Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately." | 3.91 | Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. ( Alexander, GC; Heyward, J; Lurie, P; Olson, L; Rollman, JE; Sharfstein, J, 2019) |
| " We describe the case of a patient suffering from breaktrough cancer pain treated with sublingual fentanyl." | 3.91 | [Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.] ( Miolo, G; Santeufemia, DA, 2019) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 3.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 3.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 3.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| " Group 1 was consisted of 353 patients whose basal cancer pain of intensity 4-7 NRS was treated weak opiates (basal analgetic- fixed combination of tramadol/paracetamol (37." | 3.85 | Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. ( Husic, S; Imamovic, S; Matic, S; Sukalo, A, 2017) |
| "The aim of this study was to prospectively assess the efficacy and safety of low doses of sublingual fentanyl (SLF) for the treatment of breakthrough pain (BTP) in cancer patients in patients who were receiving low opioid doses for background analgesia." | 3.85 | The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. ( Adile, C; Aielli, F; Casuccio, A; Cuomo, A; Marinangeli, F; Mercadante, S, 2017) |
| "A retrospective analysis was conduct on HNC patients during RT ± ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals." | 3.85 | Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. ( Albanese, S; Alongi, F; Fersino, S; Fiorentino, A; Giaj-Levra, N; Gori, S; Mazzola, R; Ricchetti, F; Tebano, U, 2017) |
| "Instanyl® (intranasal fentanyl spray) is a novel treatment for breakthrough pain (BTP) in cancer patients." | 3.80 | The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. ( Eeg, M; Greisen, H; Kongsgaard, UE, 2014) |
| " The past decade has seen clinical trials of transmucosal opioid formulations for breakthrough pain in cancer (BTPc), beginning with oral transmucosal fentanyl citrate (OTFC), followed by fentanyl buccal tablet and intranasal fentanyl spray, and most recently sublingual fentanyl tablet, fentanyl buccal soluble film, and fentanyl pectin nasal spray." | 3.79 | Evidence-based treatment of cancer-related breakthrough pain with opioids. ( Zeppetella, G, 2013) |
| "Three transmucosal fentanyl products have recently been licensed for cancer-related breakthrough pain: a sublingual tablet, a buccal/sublingual tablet and a nasal spray." | 3.77 | How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. ( England, R; Maddocks, M; Manderson, C; Wilcock, A; Zadora-Chrzastowska, S, 2011) |
| "Data from opioid-tolerant patients participating in clinical studies of fentanyl buccal tablet (FBT) for breakthrough pain (up to 18 months of clinical study case-report forms) were retrospectively reviewed and coded for abuse, overdose, and aberrant behavior." | 3.77 | Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. ( Golsorkhi, A; Messina, J; Passik, SD; Xie, F, 2011) |
| "Breakthrough cancer pain (BTCP) is associated with decreased satisfaction with around-the-clock opioid therapy." | 2.80 | Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain. ( Barker, J; Dillaha, L; Parikh, N; Rauck, R; Stearns, L, 2015) |
| "Opioid-tolerant patients with chronic cancer-related pain who experienced up to four breakthrough pain episodes daily were randomized to a starting dose of 100 or 200 μg for the titration period." | 2.80 | Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. ( Davies, A; Jarosz, J; Kleeberg, UR; Kress, HG; Mercadante, S; O'Brien, T; Poulain, P; Schneid, H, 2015) |
| " Adverse events were somnolence and other events associated with opioids were mostly mild or moderate." | 2.79 | A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. ( Adachi, I; Eguchi, K; Goto, F; Hamada, S; Kosugi, T; Kunikane, H; Matoba, M; Shima, Y; Shinozaki, K; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2014) |
| "Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min." | 2.79 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. ( España Ximénez de Enciso, I; García Velasco, P; Muñoz Garrido, JC; Velázquez Clavarana, L; Velázquez Rivera, I, 2014) |
| "A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study." | 2.77 | Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. ( Adile, C; Aielli, F; Casuccio, A; Gatti, A; Lo Presti, C; Mercadante, S; Porzio, G, 2012) |
| "Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about 180,000 cancer deaths per year." | 2.66 | Is pain part of a systemic syndrome in head and neck cancer? ( Argenone, A; Bossi, P; Depenni, R; Ghiani, M, 2020) |
| "Treatment directed towards painful metastases must be considered." | 2.66 | Breakthrough cancer pain in 2020. ( Klepstad, P; Løhre, ET; Thronæs, M, 2020) |
| "However, the treatment of breakthrough pain should be adjusted to suit specific patient requirements." | 2.61 | The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. ( Brząkała, J; Leppert, W, 2019) |
| "Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB." | 2.58 | Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management. ( Mercadante, S, 2018) |
| "Fentanyl is a synthetic, highly selective opioid with many desirable physicochemical properties, including a high lipophilicity and predictable pharmacokinetics." | 2.55 | Fentanyl Formulations in the Management of Pain: An Update. ( Schug, SA; Ting, S, 2017) |
| " Five studies and guidelines also suggest that oral opioids (not including TIRF products) be dosed proportionally to baseline opioids at 10%-20% of the 24-hour, around-the-clock dose." | 2.55 | Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management . ( Brant, JM; Gallagher, E; Rodgers, BB; Sundaramurthi, T, 2017) |
| "The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP)." | 2.53 | Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering. ( Candeletti, S; Romualdi, P, 2016) |
| " Furthermore, it is a reasonably safe treatment, causing generally mild adverse events not leading to treatment discontinuation." | 2.52 | Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. ( Escobar, Y; Moya, J; Murillo, M; Rogríguez, D; Urrutia, G, 2015) |
| " These dosage forms offer overlapping yet distinct pharmacokinetic advantages to allow more choices for physicians and patients in the management of breakthrough cancer pain." | 2.50 | Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain. ( Chen, C; Gupta, A, 2014) |
| "Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life." | 2.49 | Fentanyl for the treatment of tumor-related breakthrough pain. ( Bornemann-Cimenti, H; Sandner-Kiesling, A; Szilagyi, IS; Wejbora, M, 2013) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs despite relatively stable and adequately controlled background pain." | 2.49 | [Management of breakthrough cancer pain]. ( Sláma, O, 2013) |
| "Fentanyl is a synthetic opioid characterized by rapid absorption and start of the analgesic effects." | 2.49 | Optimal management of breakthrough cancer pain (BCP). ( Antón, A; Casas, A; Cruz, JJ; Escobar, Y; Gálvez, R; Juliá, J; López, R; Mañas, A; Margarit, C; Zaragozá, F, 2013) |
| " placebo in the first 30 minutes after dosing (FBT provided an 83% probability of superior pain relief, ODT 66%, and OTFC 73% vs." | 2.49 | Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. ( Bennett, MI; Fullarton, JR; Jandhyala, R, 2013) |
| " The primary outcome was improvement in PID during the first 60 min after dosing (15-60 min)." | 2.48 | Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. ( Fullarton, J; Jandhyala, R, 2012) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain." | 2.48 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. ( Mercadante, S, 2012) |
| "Breakthrough pain is characterized by a sudden onset and rapid increase in the pain level and should be treated with correspondingly rapidly effective opioids." | 2.47 | [Cancer breakthrough pain. Indications for rapidly effective opioids]. ( Bardenheuer, HJ; Kessler, J, 2011) |
| "The usual management of cancer related breakthrough pain is with supplemental doses of analgesics (commonly opioids) at a dose proportional to the total around-the-clock opioid dose." | 2.47 | Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. ( Zeppetella, G, 2011) |
| " Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results." | 2.47 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. ( Elsner, F; Porta-Sales, J; Tagarro, I; Zeppetella, G, 2011) |
| "In comparison with other tumors, in patients with MM BTcP was more predictable (p=0." | 1.91 | Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study. ( Caraceni, A; Cuomo, A; Mammucari, M; Marchetti, P; Mediati, RD; Mercadante, S; Natoli, S; Tonini, G, 2023) |
| "Patients who required treatment of breakthrough pain had higher patient-controlled epidural boluses demands-to-delivery ratio." | 1.91 | Association between breakthrough labor pain, patient-controlled epidural analgesia use, and numeracy: A pilot observational study. ( Kim, J; Klumpner, TT; Lange, EMS; McCarthy, RJ; Thakkar, K; Toledo, P; Wong, CA, 2023) |
| " A strong consensus was achieved regarding which pharmacological treatment (transmucosal fentanyl) and dosing method (start low and go slow) are the most suitable for the older population." | 1.51 | Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. ( Alarcón, MDL; Cabezón-Gutiérrez, L; Estévez, FV; Jiménez-López, AJ; Martín-Arroyo, JMT; Padrós, MC; Rebollo, MA; Sanz-Yagüe, A, 2019) |
| "Adverse drug reactions were registered in 3%." | 1.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| "Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen." | 1.48 | Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2018) |
| " TIRF use was mainly related to background opioid dosage and the patient's self-sufficiency in taking medication." | 1.48 | Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. ( Calvieri, A; Casale, G; Dardeli, A; Eusepi, G; Giannarelli, D; Magnani, C; Mastroianni, C; Restuccia, MR, 2018) |
| " Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate)." | 1.48 | Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. ( Cho, HN; Koo, DH; Kwon, MY; Lee, SS; Lee, YG; Oh, S, 2018) |
| "No published studies have looked at the dosing and use of rapid onset fentanyl preparations in children." | 1.46 | The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. ( Anderson, AK; Burke, K; Coombes, L, 2017) |
| "Fentanyl has a strong first pass effect when administered orally and resorbed enterally, however it is well suited for transmucosal administration, e." | 1.46 | [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. ( Überall, MA, 2017) |
| "The recommended dosing interval for transdermal fentanyl is every 72 h." | 1.43 | A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. ( Hirayama, Y; Horiuchi, I; Ishitani, K; Kato, J; Koike, K; Kusakabe, T; Machino, T; Mihara, H; Nagasako, T; Nishisato, T; Terui, T; Yamakage, M, 2016) |
| "The pharmacokinetics of the sublingual fentanyl orally disintegrating tablet appear to be negatively affected by the presence of salivary gland hypofunction, although the moistening of the oral cavity before dosing results in a pharmacokinetic profile similar to that seen with the giving of pilocarpine hydrochloride." | 1.43 | The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. ( Buchanan, A; Davies, A; Mundin, G; Vriens, J; Waghorn, M; Webber, K, 2016) |
| "Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain." | 1.42 | Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. ( Bedard, G; Buchanan, A; Chow, E; Davies, A; Hawley, P; McDonald, R; Popovic, M; Wong, E, 2015) |
| "Breakthrough pain affects 40%-90% of patients with cancer pain." | 1.42 | Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study. ( Borchgrevink, PC; Fredheim, OM; Mahic, M; Skurtveit, S, 2015) |
| " Differences exist between TIRFs regarding formulation design and dosing to treat BTCP." | 1.42 | Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. ( Atayee, RS; Chang, A; Ma, JD; Revta, C; Roeland, EJ, 2015) |
| "IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures." | 1.40 | Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. ( Ashmawi, HA; Cascudo, GM; de Santana Neto, J; Guimaraes, GM; Neto, JO; Sousa, AM, 2014) |
| "Pain is a symptom of cancer and is categorized in two forms: background pain to be treated with analgesics, and breakthrough cancer pain (BTcP), which needs drug treatment on demand." | 1.40 | Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. ( Oradei, M; Ruggeri, M; Turriziani, A, 2014) |
| " Dosing proportional to basic opioid regimen is now proposed as an alternative to dose titration." | 1.39 | Treatment of breakthrough cancer pain: to titrate or to proportionate? ( Hans, GH, 2013) |
| "Uncontrolled prescription for non-cancer pain must be criticized due to the problem of addiction." | 1.39 | [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society]. ( Heuser-Grannemann, E; Junker, U; Schenk, M; Wiese, CH; Wirz, S; Zimmermann, M, 2013) |
| "FPNS is indicated for the treatment of breakthrough pain in cancer patients who are tolerant to opioid therapy for their underlying persistent cancer pain." | 1.38 | Fentanyl pectin nasal spray for breakthrough cancer pain. ( Gabrail, N; Taylor, DR, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 142 (87.65) | 24.3611 |
| 2020's | 20 (12.35) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez, AT | 1 |
| Viejo, MN | 1 |
| Maradey, P | 1 |
| Canal-Sotelo, J | 1 |
| Mancilla, PG | 1 |
| Rivero, SG | 1 |
| Casillas, IR | 1 |
| Abián, MH | 1 |
| Bermudo, CL | 1 |
| Cascella, M | 1 |
| Monaco, F | 1 |
| Nocerino, D | 1 |
| Chinè, E | 1 |
| Carpenedo, R | 1 |
| Picerno, P | 1 |
| Migliaccio, L | 1 |
| Armignacco, A | 1 |
| Franceschini, G | 2 |
| Coluccia, S | 1 |
| Gennaro, PD | 1 |
| Tracey, MC | 1 |
| Forte, CA | 1 |
| Tafuri, M | 1 |
| Crispo, A | 1 |
| Cutugno, F | 1 |
| Vittori, A | 1 |
| Natoli, S | 2 |
| Cuomo, A | 6 |
| Kwon, MY | 2 |
| Lee, MY | 1 |
| Han, YJ | 1 |
| Lee, SH | 1 |
| Kim, EJ | 1 |
| Park, S | 1 |
| Lee, YG | 2 |
| Koo, DH | 2 |
| Mercadante, S | 22 |
| Caraceni, A | 2 |
| Mammucari, M | 2 |
| Marchetti, P | 3 |
| Mediati, RD | 1 |
| Tonini, G | 1 |
| Thantiprechapong, T | 1 |
| Tilagul, T | 1 |
| Vasikasin, V | 1 |
| Lange, EMS | 1 |
| Kim, J | 1 |
| Klumpner, TT | 1 |
| McCarthy, RJ | 1 |
| Wong, CA | 1 |
| Thakkar, K | 1 |
| Toledo, P | 1 |
| Kaplan, S | 1 |
| Bergamasco, A | 1 |
| Sergerie, M | 1 |
| Castilloux, AM | 1 |
| Moride, Y | 1 |
| Bossi, P | 3 |
| Ghiani, M | 1 |
| Argenone, A | 1 |
| Depenni, R | 1 |
| Norman, C | 1 |
| Maynard, L | 1 |
| Lee, A | 1 |
| Landau, R | 1 |
| Lavin, T | 1 |
| Goodman, S | 1 |
| Menon, P | 1 |
| Smiley, R | 1 |
| Camps Herrero, C | 1 |
| Batista, N | 1 |
| Díaz Fernández, N | 1 |
| Escobar Álvarez, Y | 1 |
| Gonzalo Gómez, A | 1 |
| Isla Casado, D | 1 |
| Salud, A | 1 |
| Terrasa Pons, J | 1 |
| Guillem Porta, V | 1 |
| Løhre, ET | 1 |
| Thronæs, M | 2 |
| Klepstad, P | 1 |
| Ghafoor, I | 1 |
| Siddiqui, A | 1 |
| Hafeez, H | 1 |
| Usman, HM | 1 |
| Arrieta Loitegui, M | 1 |
| Caro Teller, JM | 1 |
| Rosas Espinoza, C | 1 |
| Ferrari Piquero, JM | 1 |
| Chiou, TJ | 1 |
| Chao, TC | 1 |
| Chao, TY | 1 |
| Huang, JS | 1 |
| Chang, YF | 1 |
| Wang, CH | 1 |
| Amezcua, V | 1 |
| Doello, K | 1 |
| González-Callejas, D | 1 |
| Satomi, M | 1 |
| Kono, T | 1 |
| Giuliani, J | 1 |
| Fiorica, F | 1 |
| Sacchetto, A | 1 |
| Vaccari, F | 1 |
| Bonetti, A | 1 |
| Hashemi, M | 1 |
| Zali, A | 1 |
| Golmakani, E | 1 |
| Delshad, MH | 1 |
| Shadnoush, M | 1 |
| Akbari, ME | 1 |
| Valtola, A | 1 |
| Laakso, M | 1 |
| Hakomäki, H | 1 |
| Anderson, BJ | 1 |
| Kokki, H | 1 |
| Ranta, VP | 1 |
| Rinne, V | 1 |
| Kokki, M | 1 |
| Jamieson, L | 2 |
| Harrop, E | 2 |
| Johnson, M | 1 |
| Liossi, C | 1 |
| Mott, C | 1 |
| Oulton, K | 1 |
| Skene, SS | 1 |
| Wong, IC | 1 |
| Howard, RF | 1 |
| Schug, SA | 2 |
| Ting, S | 1 |
| Yomiya, K | 3 |
| Kaneshima, M | 1 |
| Kyosaka, B | 1 |
| Warita, E | 1 |
| Hosonuma, R | 1 |
| Osato, S | 1 |
| Brant, JM | 1 |
| Rodgers, BB | 1 |
| Gallagher, E | 1 |
| Sundaramurthi, T | 1 |
| Cortesi, PA | 2 |
| D'Angiolella, LS | 1 |
| Vellucci, R | 3 |
| Allegri, M | 1 |
| Casale, G | 2 |
| Favaretti, C | 1 |
| Kheiraoui, F | 1 |
| Cesana, G | 1 |
| Mantovani, LG | 1 |
| Guitart, J | 5 |
| Vargas, MI | 4 |
| De Sanctis, V | 5 |
| Folch, J | 5 |
| Salazar, R | 5 |
| Fuentes, J | 5 |
| Coma, J | 5 |
| Ferreras, J | 5 |
| Moya, J | 6 |
| Tomás, A | 5 |
| Estivill, P | 4 |
| Rodelas, F | 5 |
| Jiménez, AJ | 4 |
| Sanz, A | 3 |
| Choy, TH | 1 |
| Ho, WHP | 1 |
| Wong, ICK | 1 |
| Masel, EK | 1 |
| Landthaler, R | 1 |
| Gneist, M | 1 |
| Watzke, HH | 1 |
| Prieto, I | 1 |
| Pardo, J | 2 |
| Luna, J | 1 |
| Marin, JP | 1 |
| Olivera, J | 1 |
| Garcia, AJ | 1 |
| Perez, AM | 1 |
| Breivik, H | 1 |
| Husic, S | 1 |
| Imamovic, S | 1 |
| Matic, S | 1 |
| Sukalo, A | 1 |
| Coombes, L | 1 |
| Burke, K | 1 |
| Anderson, AK | 1 |
| Überall, MA | 1 |
| Lux, EA | 1 |
| Schwittay, A | 1 |
| Kleeberg, UR | 3 |
| Papke, J | 1 |
| Yen, TY | 1 |
| Chiou, JF | 1 |
| Chiang, WY | 1 |
| Su, WH | 1 |
| Huang, MY | 1 |
| Hu, MH | 1 |
| Wu, SC | 1 |
| Lai, YL | 1 |
| Michenot, N | 1 |
| Rostaing, S | 1 |
| Baron, L | 1 |
| Faure, S | 1 |
| Jovenin, N | 1 |
| Hubault, P | 1 |
| Delorme, T | 1 |
| Collin, E | 1 |
| Filbet, M | 1 |
| Chvetzoff, G | 1 |
| Delorme, C | 1 |
| Minello, C | 1 |
| Magnet, M | 1 |
| Ammar, D | 1 |
| Krakowski, I | 1 |
| Poulain, P | 3 |
| Yousef, AA | 1 |
| Alzeftawy, AE | 1 |
| Magnani, C | 1 |
| Giannarelli, D | 1 |
| Calvieri, A | 1 |
| Dardeli, A | 1 |
| Eusepi, G | 1 |
| Restuccia, MR | 1 |
| Mastroianni, C | 1 |
| Adile, C | 8 |
| Masedu, F | 2 |
| Costanzi, A | 2 |
| Aielli, F | 7 |
| Gunnellini, M | 1 |
| Rollman, JE | 1 |
| Heyward, J | 1 |
| Olson, L | 1 |
| Lurie, P | 1 |
| Sharfstein, J | 1 |
| Alexander, GC | 1 |
| Santeufemia, DA | 1 |
| Miolo, G | 1 |
| Brząkała, J | 1 |
| Leppert, W | 1 |
| Alarcón, MDL | 1 |
| Estévez, FV | 1 |
| Cabezón-Gutiérrez, L | 1 |
| Padrós, MC | 1 |
| Martín-Arroyo, JMT | 1 |
| Rebollo, MA | 1 |
| Jiménez-López, AJ | 1 |
| Sanz-Yagüe, A | 1 |
| Mena, A | 1 |
| Jiménez, E | 1 |
| Aymar, N | 1 |
| Ortiz, I | 1 |
| Roncero, R | 1 |
| Mestre, F | 1 |
| Vidal, M | 1 |
| Triarico, S | 1 |
| Capozza, MA | 1 |
| Mastrangelo, S | 1 |
| Attinà, G | 1 |
| Maurizi, P | 1 |
| Ruggiero, A | 1 |
| Diez-Picazo, LD | 1 |
| Guasch, E | 1 |
| Brogly, N | 1 |
| Gilsanz, F | 1 |
| Fidkowski, CW | 1 |
| Shah, S | 1 |
| Alsaden, MR | 1 |
| Valenti, M | 1 |
| Handsaker, S | 2 |
| Dempsey, L | 2 |
| Fabby, C | 2 |
| Grassin-Delyle, S | 1 |
| Naline, E | 1 |
| Devillier, P | 1 |
| Perelman, M | 3 |
| Leake, S | 1 |
| Dietrich, E | 2 |
| Gums, JG | 2 |
| Zeppetella, G | 5 |
| Porzio, G | 3 |
| Averna, L | 1 |
| Ficorella, C | 1 |
| Casuccio, A | 10 |
| Elsner, F | 2 |
| Pastrana, T | 1 |
| Plock, N | 1 |
| Facius, A | 2 |
| Hartmann, L | 1 |
| Baumann, S | 1 |
| Nave, R | 2 |
| McWilliams, K | 1 |
| Fallon, M | 1 |
| Bornemann-Cimenti, H | 2 |
| Wejbora, M | 2 |
| Szilagyi, IS | 2 |
| Sandner-Kiesling, A | 2 |
| Kuo, KL | 1 |
| Saokaew, S | 1 |
| Stenehjem, DD | 1 |
| Meissner, W | 1 |
| Sabatowski, R | 1 |
| Beutlhauser, T | 1 |
| Oeltjenbruns, J | 1 |
| Schäfer, M | 1 |
| Sláma, O | 1 |
| Webster, LR | 1 |
| Slevin, KA | 1 |
| Narayana, A | 2 |
| Earl, CQ | 1 |
| Yang, R | 2 |
| Prestia, G | 2 |
| Vargas, I | 1 |
| Vázquez, JM | 1 |
| Ribera, H | 1 |
| Arilla, M | 1 |
| Aberasturi, T | 1 |
| Sintes, D | 1 |
| Lombán, E | 1 |
| Hans, GH | 1 |
| Ketterer, W | 1 |
| Kosugi, T | 1 |
| Hamada, S | 1 |
| Takigawa, C | 2 |
| Shinozaki, K | 1 |
| Kunikane, H | 1 |
| Goto, F | 2 |
| Tanda, S | 2 |
| Shima, Y | 2 |
| Matoba, M | 2 |
| Adachi, I | 2 |
| Yoshimoto, T | 2 |
| Eguchi, K | 2 |
| Taylor, D | 2 |
| Radbruch, L | 2 |
| Revnic, J | 2 |
| Torres, LM | 3 |
| Ellershaw, JE | 2 |
| Davies, AN | 2 |
| Sousa, AM | 1 |
| de Santana Neto, J | 1 |
| Guimaraes, GM | 1 |
| Cascudo, GM | 1 |
| Neto, JO | 1 |
| Ashmawi, HA | 1 |
| Velázquez Rivera, I | 1 |
| Muñoz Garrido, JC | 1 |
| García Velasco, P | 1 |
| España Ximénez de Enciso, I | 1 |
| Velázquez Clavarana, L | 1 |
| Novotna, S | 1 |
| Valentova, K | 1 |
| Fricova, J | 1 |
| Richterova, E | 1 |
| Harabisova, S | 1 |
| Bullier, F | 1 |
| Trinquet, F | 2 |
| Kongsgaard, UE | 1 |
| Eeg, M | 2 |
| Greisen, H | 1 |
| England, R | 1 |
| Maddocks, M | 1 |
| Manderson, C | 1 |
| Zadora-Chrzastowska, S | 1 |
| Wilcock, A | 1 |
| Jandhyala, R | 3 |
| Fullarton, J | 1 |
| Passik, SD | 2 |
| Ruggeri, M | 1 |
| Turriziani, A | 1 |
| Oradei, M | 1 |
| Davis, MP | 4 |
| Bruera, E | 1 |
| Fullarton, JR | 2 |
| Bennett, MI | 2 |
| Shimoyama, N | 2 |
| Gomyo, I | 2 |
| Katakami, N | 1 |
| Okada, M | 1 |
| Yukitoshi, N | 2 |
| Ohta, E | 2 |
| Shimoyama, M | 2 |
| Granata, R | 2 |
| Bertulli, R | 1 |
| Saita, L | 1 |
| Locati, L | 1 |
| Bergamini, C | 1 |
| Mirabile, A | 1 |
| Imbimbo, M | 1 |
| Resteghini, C | 1 |
| Licitra, L | 1 |
| Zucco, F | 1 |
| Bonezzi, C | 1 |
| Fornasari, D | 1 |
| Gombert-Handoko, KB | 1 |
| Rauck, R | 2 |
| Parikh, N | 3 |
| Dillaha, L | 1 |
| Barker, J | 1 |
| Stearns, L | 1 |
| Davies, A | 4 |
| Jarosz, J | 2 |
| O'Brien, T | 2 |
| Schneid, H | 2 |
| Kress, HG | 2 |
| Bedard, G | 1 |
| McDonald, R | 1 |
| Hawley, P | 1 |
| Buchanan, A | 2 |
| Popovic, M | 1 |
| Wong, E | 1 |
| Chow, E | 1 |
| Chen, C | 1 |
| Gupta, A | 1 |
| Cortegiani, A | 2 |
| Valle, A | 1 |
| Villari, P | 1 |
| Teramoto, O | 1 |
| Kojima, K | 1 |
| Higuchi, H | 1 |
| Caruselli, A | 1 |
| Meli, MR | 1 |
| Bellavia, G | 1 |
| Tuttolomondo, A | 1 |
| Doulton, B | 1 |
| Popper, L | 1 |
| Jaatun, E | 1 |
| Kvitberg, M | 1 |
| Kaasa, S | 1 |
| Cánovas-Martínez, L | 1 |
| Carceller-Ruiz, JJ | 1 |
| Díaz-Parada, P | 1 |
| Illodo-Miramontes, G | 1 |
| Freire-Vila, E | 1 |
| De la Iglesia-López, A | 1 |
| Iglesias, BG | 1 |
| López-Ulloa, B | 1 |
| Domínguez-Suárez, E | 1 |
| Camba-Rodríguez, A | 1 |
| Fredheim, OM | 1 |
| Mahic, M | 1 |
| Skurtveit, S | 1 |
| Borchgrevink, PC | 1 |
| Trinidad, JM | 1 |
| Calderón, E | 1 |
| Benitez, D | 1 |
| De Franceschi, L | 1 |
| Mura, P | 1 |
| Schweiger, V | 1 |
| Vencato, E | 1 |
| Quaglia, FM | 1 |
| Delmonte, L | 1 |
| Evangelista, M | 1 |
| Polati, E | 1 |
| Olivieri, O | 1 |
| Finco, G | 1 |
| Koike, K | 1 |
| Terui, T | 1 |
| Nagasako, T | 1 |
| Horiuchi, I | 1 |
| Machino, T | 1 |
| Kusakabe, T | 1 |
| Hirayama, Y | 1 |
| Mihara, H | 1 |
| Yamakage, M | 1 |
| Kato, J | 1 |
| Nishisato, T | 1 |
| Ishitani, K | 1 |
| Chang, A | 1 |
| Roeland, EJ | 1 |
| Atayee, RS | 1 |
| Revta, C | 1 |
| Ma, JD | 1 |
| Rogríguez, D | 1 |
| Urrutia, G | 1 |
| Escobar, Y | 2 |
| Murillo, M | 1 |
| Mundin, G | 1 |
| Vriens, J | 1 |
| Webber, K | 1 |
| Waghorn, M | 1 |
| Minkowitz, H | 1 |
| Bull, J | 1 |
| Brownlow, RC | 1 |
| Tshibuyl, PN | 1 |
| Olang, PO | 1 |
| Ogutu, O | 1 |
| Chokwe, TM | 1 |
| Garnock-Jones, KP | 1 |
| Alberts, DS | 1 |
| Smith, CC | 1 |
| Rauck, RL | 2 |
| Meijler, WJ | 1 |
| Romualdi, P | 2 |
| Candeletti, S | 1 |
| Fanelli, G | 1 |
| Pannuti, R | 1 |
| Peruselli, C | 1 |
| Ballantyne, JC | 1 |
| Marinangeli, F | 1 |
| Mazzola, R | 1 |
| Ricchetti, F | 1 |
| Fiorentino, A | 1 |
| Giaj-Levra, N | 1 |
| Fersino, S | 1 |
| Tebano, U | 1 |
| Albanese, S | 1 |
| Gori, S | 1 |
| Alongi, F | 1 |
| Dyer, O | 1 |
| Cho, HN | 1 |
| Oh, S | 1 |
| Lee, SS | 1 |
| Messina, J | 1 |
| Golsorkhi, A | 1 |
| Xie, F | 2 |
| Sima, L | 1 |
| Fang, WX | 1 |
| Wu, XM | 1 |
| Li, F | 1 |
| Gatti, A | 2 |
| Luis Lerzo, G | 1 |
| Ferrera, P | 1 |
| Kessler, J | 1 |
| Bardenheuer, HJ | 1 |
| Porta-Sales, J | 1 |
| Tagarro, I | 1 |
| Darwish, M | 1 |
| Núñez-Olarte, JM | 1 |
| Alvarez-Jiménez, P | 1 |
| Nalamachu, SR | 1 |
| Wallace, MS | 1 |
| Hassman, D | 1 |
| Howell, J | 1 |
| Hansen, MS | 1 |
| Mathiesen, O | 1 |
| Trautner, S | 1 |
| Dahl, JB | 1 |
| Taylor, DR | 1 |
| Gabrail, N | 1 |
| Paech, MJ | 1 |
| Bloor, M | 1 |
| Lo Presti, C | 1 |
| Veldhorst-Janssen, NM | 1 |
| Fiddelers, AA | 1 |
| Zandstra, H | 2 |
| Kessels, AG | 1 |
| Marcus, MA | 1 |
| Neef, C | 1 |
| van der Kuy, PH | 1 |
| Smith, H | 1 |
| Kaessner, N | 1 |
| Roepcke, S | 1 |
| Lahu, G | 1 |
| Füessl, HS | 1 |
| Stiefelhagen, P | 1 |
| Gallagher, R | 1 |
| Meriggi, F | 1 |
| Zaniboni, A | 1 |
| Mañas, A | 1 |
| Juliá, J | 1 |
| Gálvez, R | 1 |
| Zaragozá, F | 1 |
| Margarit, C | 1 |
| López, R | 1 |
| Casas, A | 1 |
| Antón, A | 1 |
| Cruz, JJ | 1 |
| Wirz, S | 1 |
| Wiese, CH | 1 |
| Zimmermann, M | 1 |
| Junker, U | 1 |
| Heuser-Grannemann, E | 1 |
| Schenk, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units[NCT02840500] | 101 participants (Actual) | Observational | 2016-06-27 | Completed | |||
| Fentanyl Buccal Soluble Films Feasible Dose Range Study for Breakthrough Pain in Taiwanese Cancer Patients[NCT03669263] | 36 participants (Actual) | Interventional | 2014-11-25 | Completed | |||
| A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain[NCT00813488] | Phase 3 | 213 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain in Gynecologic Cancer Patients With Chronic Cancer Pain : A Randomized Double Blind Controlled Trial[NCT05037539] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2021-06-15 | Completed | ||
| Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer[NCT01842893] | Phase 3 | 91 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)[NCT01326689] | Phase 3 | 42 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients[NCT00684632] | Phase 3 | 51 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients[NCT03895762] | 143 participants (Actual) | Observational | 2017-07-04 | Completed | |||
| A Dose Titrated Clinical Trial With a Placebo-controlled, Double-blind, Randomised, Cross-over Phase to Demonstrate the Efficacy of 400 μg Intranasal Fentanyl (INFS) Dose Strength, and to Evaluate 12 Weeks Safety and Nasal Tolerability of All Dose Strengt[NCT01429051] | Phase 3 | 46 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain[NCT00538850] | Phase 3 | 130 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures[NCT01756651] | Phase 1 | 20 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. Here it was assessed 2 months after the start of the open-label extension period.~The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination)." (NCT00813488)
Timeframe: Two months after start of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination), which correspond to 1, 2, or 3 months after the start of the open-label extension period." (NCT00813488)
Timeframe: 3 months after start of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.6 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination)." (NCT00813488)
Timeframe: End of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination) which correspond to 1, 2, or 3 months after the start of the open-label extension period." (NCT00813488)
Timeframe: One month after start of open-label extension
| Intervention | Unit on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.6 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID10 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 10 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 10 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | .35 |
| Immediate-release Oxycodone (OXY) | .29 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID15 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 15 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 15 minutes after dosing
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.88 |
| Immediate-release Oxycodone (OXY) | 0.76 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID30 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 30 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 30 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.10 |
| Immediate-release Oxycodone (OXY) | 1.79 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID45 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 45 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 45 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 3.13 |
| Immediate-release Oxycodone (OXY) | 2.85 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID5 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 5 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 5 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | .08 |
| Immediate-release Oxycodone (OXY) | .06 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID60 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 60 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 60 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 3.65 |
| Immediate-release Oxycodone (OXY) | 3.48 |
The PR score 5 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 5 minutes after treatment
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.11 |
| Immediate-release Oxycodone (OXY) | 0.10 |
The PR score 10 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 10 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.32 |
| Immediate-release Oxycodone (OXY) | 0.26 |
The PR score 15 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 15 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.68 |
| Immediate-release Oxycodone (OXY) | 0.56 |
The PR score 30 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 30 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.48 |
| Immediate-release Oxycodone (OXY) | 1.22 |
The PR score 45 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 45 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.14 |
| Immediate-release Oxycodone (OXY) | 1.90 |
The PR score 60 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 60 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.44 |
| Immediate-release Oxycodone (OXY) | 2.27 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. This was assessed 1 month after start of the open-label extension period. (NCT00813488)
Timeframe: One month after start of open-label treatment
| Intervention | Unit on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.6 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed 2 months after the start of the open-label extension period. (NCT00813488)
Timeframe: 2 months after start of open-label extension period
| Intervention | Units on scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.8 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed 3 months after the start of the open-label extension period. (NCT00813488)
Timeframe: 3 months after start of open-label extension period
| Intervention | Units on scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.7 |
| Standard of Care (SOC) | 0.8 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed at the conclusion of the open-label extension period. (NCT00813488)
Timeframe: At conclusion of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.9 |
The PR score at set intervals after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). The maximum TOTPAR score that could be achieved at 60 minutes is equal to 16; thus, %TOTPAR at 60 minutes is (TOTPAR60 /16) x 100.The % TOTPAR achieved 60 minutes after the administration of study drug was calculated during the double-blind treatment phase. (NCT00813488)
Timeframe: From 5 minutes through 60 minutes after study drug treatment
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 40.11 |
| Immediate-release Oxycodone (OXY) | 35.59 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain. The PID10 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 10 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. This was assessed during the double-blind treatment period. (NCT00813488)
Timeframe: Immediately before treatment and 10 minutes after treatment.
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 4.83 |
| Immediate-release Oxycodone (OXY) | 3.89 |
Pain intensity (PI) scores were assessed during the double-blind treatment period on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain. The PID15 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 15 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Baseline (immediately pre-dose) and 15 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 12.38 |
| Immediate-release Oxycodone (OXY) | 10.38 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID30 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 30 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Pre-dose and 30 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 29.72 |
| Immediate-release Oxycodone (OXY) | 25.03 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID45 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 45 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 45 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 44.84 |
| Immediate-release Oxycodone (OXY) | 40.49 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID5 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 5 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 5 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.01 |
| Immediate-release Oxycodone (OXY) | 0.73 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID60 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 60 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 60 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 52.61 |
| Immediate-release Oxycodone (OXY) | 49.47 |
PI scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. SPID30 were derived from PID values. The SPID30 scores during the double-blind treatment phase were calculated as the time- weighted sum of the PID scores from 5 through 30 minutes,after the administration of study drug. SPID30 = (⅓ x PID5) + (⅓ x PID10) + (⅓ x PID15) + PID30. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: From 5 minutes after dosing through 30 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.54 |
| Immediate-release Oxycodone (OXY) | 2.16 |
"PI scores were assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine during the double-blind treatment period. The SPID60 was derived from PID values. The SPID60 scores during the double-blind treatment phase were calculated as the time- weighted sum of the PID scores from 5 through 60 minutes,after the administration of the study drug.~SPID60 = SPID30 + PID45 + PID60. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry." (NCT00813488)
Timeframe: From 5 minutes after dosing through 60 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 9.32 |
| Immediate-release Oxycodone (OXY) | 8.50 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 5 minutes or less was compared. (NCT00813488)
Timeframe: From time study drug was taken until 5 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 55 |
| Immediate-release Oxycodone (OXY) | 50 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 10 minutes or less was compared. (NCT00813488)
Timeframe: From study drug treatment until 10 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 226 |
| Immediate-release Oxycodone (OXY) | 219 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 15 minutes or less was compared. (NCT00813488)
Timeframe: From study drug administration to 15 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 515 |
| Immediate-release Oxycodone (OXY) | 451 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 30 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration till 30 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1004 |
| Immediate-release Oxycodone (OXY) | 877 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 45 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 45 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1217 |
| Immediate-release Oxycodone (OXY) | 1150 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 60 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 60 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1271 |
| Immediate-release Oxycodone (OXY) | 1239 |
Time to MPR (subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. (NCT00813488)
Timeframe: From time study drug was taken until 5 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 21 |
| Immediate-release Oxycodone (OXY) | 26 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 10 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 10 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 88 |
| Immediate-release Oxycodone (OXY) | 91 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 15 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 15 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 230 |
| Immediate-release Oxycodone (OXY) | 212 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 30 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 30 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 613 |
| Immediate-release Oxycodone (OXY) | 503 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 45 minutes or less was compared. (NCT00813488)
Timeframe: From study drug administration until 45 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 983 |
| Immediate-release Oxycodone (OXY) | 864 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 60 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 60 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1139 |
| Immediate-release Oxycodone (OXY) | 1047 |
"The mean TOTPAR at 60 minutes will be calculated for each episode as the weighted sum of Pain Relief (PR) scores (5-point Likert scale, 0 = none to 4 = complete) at each assessment of PR (during the double-blind treatment period) until 60 minutes after study drug administration, as follows:~TOTPAR60 =(⅓ x PR5)+ (⅓ x PR10) +(⅓ x PR15)+ PR30 + PR45 + PR60. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry." (NCT00813488)
Timeframe: From 5 minutes to 60 minutes after dosing
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 6.43 |
| Immediate-release Oxycodone (OXY) | 5.70 |
Any use of standard rescue medication after the administration of study drug for relief of Breakthrough Pain (BTP) during the double-blind treatment phase was recorded in the patient's diary. The number of breakthrough pain episodes for which study drug treatment was administered and which required rescue medication use was recorded. (NCT00813488)
Timeframe: Throughout the double-blind treatment period
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 39 |
| Immediate-release Oxycodone (OXY) | 41 |
The BTP preference questionnaire is a questionnaire used to measure patients' preference for FBT or immediate-release oxycodone for management of BTP. The question is used to determine a patient's preference between the study drugs given in the 2 double-blind treatment periods. The patient was asked to select 1 of the following: 1, a preference for study drug used in the 1st double-blind treatment period; 2, a preference for study drug used in the 2nd double-blind treatment period; or 3, no preference. (NCT00813488)
Timeframe: At Visit 6 ( up to 42 days depending upon how long it takes the patient to manage their BTP) after completion of both double-blind treatment periods.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Preferred FBT | Preferred Oxycodone | No Preference | Missing | |
| Total | 62 | 46 | 23 | 12 |
"The medication performance assessment assessed study drug performance on a 5-point categorical scale of 0-4 (0=poor, 1=fair,2=good, 3=very good, 4=excellent) 30 minutes after administration of study drug during the double-blind treatment periods and for the first 5 BTP episodes after each visit during the open-label extension period were recorded in the patient's paper diary. Patients were asked How well did your study medication perform in controlling this breakthrough pain episode? The number of episodes rated for each category were recorded." (NCT00813488)
Timeframe: 30 minutes post-treatment
| Intervention | Episodes (Number) | |||||
|---|---|---|---|---|---|---|
| Excellent | Very Good | Good | Fair | Poor | No Response | |
| Fentanyl Buccal Tablet (FBT) | 49 | 125 | 378 | 416 | 341 | 33 |
| Immediate-release Oxycodone (OXY) | 16 | 104 | 304 | 391 | 489 | 30 |
"The medication performance assessment assessed study drug performance on a 5-point categorical scale of 0-4 (0=poor, 1=fair,2=good, 3=very good, 4=excellent) 60 minutes after administration of study drug during the double-blind treatment periods and for the first 5 BTP episodes after each visit during the open-label extension period were recorded in the patient's paper diary. Patients were asked How well did your study medication perform in controlling this breakthrough pain episode? The number of episodes rated for each category were recorded." (NCT00813488)
Timeframe: 60 minutes post-treatment
| Intervention | Episodes (Number) | |||||
|---|---|---|---|---|---|---|
| Excellent | Very Good | Good | Fair | Poor | No Response | |
| Fentanyl Buccal Tablet (FBT) | 160 | 371 | 508 | 181 | 92 | 30 |
| Immediate-release Oxycodone (OXY) | 119 | 313 | 565 | 179 | 136 | 22 |
"Participants assessed their general impression (GI) of treatment efficacy for treated BTP episodes at 60 minutes after first dose of study drug. The validated, categorical 5-point Verbal Rating Scale (VRS) was used for this assessment and scored as follows:~0 =poor;~1 =fair;~2 =good;~3 =very good;~4 =excellent." (NCT01429051)
Timeframe: During the efficacy phase (II), at each episode of breakthrough pain, 60 minutes after first dose of study drug.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Intranasal Fentanyl Spray (INFS) | 1.9 |
| Placebo | 1.1 |
"During the efficacy phase participants assessed their pain intensity at each breakthrough pain (BTP) episode at 0 and 10 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID10 is calculated as the difference in pain intensity from time 0 to 10 minutes. A positive value is a decrease (improvement) of the pain; a ≥ 2-point difference is considered as clinically important." (NCT01429051)
Timeframe: During the efficacy phase (II), at each episode of breakthrough pain, at 0 and 10 minutes after first dose of study drug.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Intranasal Fentanyl Spray (INFS) | 2.5 |
| Placebo | 1.4 |
"During the efficacy phase participants assessed their pain intensity at each breakthrough pain (BTP) episode at 0, 5, 30 and 60 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID is calculated as the difference in pain intensity from time 0 to each time point. A positive value is a decrease (improvement) of the pain; a ≥ 2-point difference is considered as clinically important." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug.
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| PID at 5 minutes | PID at 30 minutes | PID at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 1.3 | 3.0 | 3.3 |
| Placebo | 0.8 | 1.8 | 2.2 |
"Overall responder rate is defined as the proportion of breakthrough pain (BTP) episodes with a positive response to treatment. The following definitions of a positive response were analyzed: • greater than or equal to 1 point reduction in pain intensity (PI) from time 0, • greater than or equal to 2 point reduction in PI from time 0, and • greater than or equal to 3 point reduction in PI from time 0. Pain intensity was assessed using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | proportion of breakthrough pain episodes (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 point reduction in PI at 5 minutes | ≥ 1 point reduction in PI at 10 minutes | ≥ 1 point reduction in PI at 30 minutes | ≥ 1 point reduction in PI at 60 minutes | ≥ 2 point reduction in PI at 5 minutes | ≥ 2 point reduction in PI at 10 minutes | ≥ 2 point reduction in PI at 30 minutes | ≥ 2 point reduction in PI at 60 minutes | ≥ 3 point reduction in PI at 5 minutes | ≥ 3 point reduction in PI at 10 minutes | ≥ 3 point reduction in PI at 30 minutes | ≥ 3 point reduction in PI at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 0.61 | 0.74 | 0.81 | 0.86 | 0.33 | 0.51 | 0.60 | 0.65 | 0.18 | 0.32 | 0.45 | 0.50 |
| Placebo | 0.45 | 0.55 | 0.66 | 0.69 | 0.24 | 0.31 | 0.41 | 0.48 | 0.17 | 0.24 | 0.34 | 0.48 |
"Overall responder rate is defined as the proportion of breakthrough pain (BTP) episodes with a positive response to treatment. The following definitions of a positive response were analyzed: • Greater than 33% reduction in PI from time 0; • Greater than or equal to 50% reduction in PI from time 0. Pain intensity was assessed using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | proportion of breakthrough pain episodes (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| > 33% reduction in PI at 5 minutes | > 33% reduction in PI at 10 minutes | > 33% reduction in PI at 30 minutes | > 33% reduction in PI at 60 minutes | ≥ 50% reduction in PI at 5 minutes | ≥ 50% reduction in PI at 10 minutes | ≥ 50% reduction in PI at 30 minutes | ≥ 50% reduction in PI at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 0.23 | 0.44 | 0.55 | 0.58 | 0.11 | 0.31 | 0.49 | 0.52 |
| Placebo | 0.17 | 0.24 | 0.34 | 0.48 | 0.07 | 0.21 | 0.31 | 0.34 |
"The SPID30 and SPID60 represent the average improvement in pain intensity over the 30 minute interval and 60 minute interval, respectively. SPIDt was calculated as the area under the curve (AUC) for Pain Intensity Difference over the time interval 0 to t minutes, respectively, divided by the length of the time interval (t minutes). A positive value is a decrease (improvement) of the pain.~Pain intensity was assessed at 0, 5, 30 and 60 minutes after study drug using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID is calculated as the difference in pain intensity from time 0 to each time point." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| SPID30 | SPID60 | |
| Intranasal Fentanyl Spray (INFS) | 0.6 | 0.7 |
| Placebo | 0.4 | 0.5 |
Medical examination of the nasal cavity by rhinoscopy was performed by an oto-rhino-laryngologist before the start of study treatment and at 12 weeks. Signs and any abnormalities were observed for each nostril using the following 4 points assessment scale: • 0 =not present; • 1 =present in a mild degree; • 2 =present in a moderate degree; • 3 =present in a severe degree. A difference in score of 1 or more from Baseline to the end of treatment represented a worsening, while a negative value indicated an improvement of the observed clinical sign. The oto-rhino-laryngologist also assessed whether worsening of a sign was related to study drug. Assessments for both left and right nostrils are presented together. The incidence is calculated as the number of assessments (n) in the improvement or worsening category divided by the number of assessments with a non-missing score for the Nasal Mucosa or Abnormality assessment. Only those signs or abnormalities with n>0 were included (NCT01429051)
Timeframe: Baseline and at 12 weeks
| Intervention | proportion of nostril assessments (Number) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change of color: Improvement | Change of color: Worsening | Change of color: Worsening related to study drug | Inflammation: Improvement | Inflammation: Worsening | Inflammation: Worsening related to study drug | Sore nose: Improvement | Sore nose: Worsening | Sore nose: Worsening related to study drug | Ulceration: Improvement | Ulceration: Worsening | Ulceration: Worsening related to study drug | Dry nose: Improvement | Dry nose: Worsening | Dry nose: Worsening related to study drug | Runny nose: Improvement | Runny nose: Worsening | Runny nose: Worsening related to study drug | Stuffed nose: Improvement | Stuffed nose: Worsening | Stuffed nose: Worsening related to study drug | Oedema: Improvement | Oedema: Worsening | Oedema: Worsening related to study drug | Epistaxis: Improvement | Epistaxis: Worsening | Epistaxis: Worsening related to study drug | |
| Intranasal Fentanyl Spray (INFS) | 0.06 | 0.09 | 0.09 | 0.04 | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | NA | 0.04 | 0.04 | 0.09 | 0.06 | NA | 0.04 | 0.13 | 0.10 | 0.06 | 0.17 | 0.08 | 0.04 | 0.17 | 0.08 | 0.02 | 0.02 | 0.02 |
The severity (intensity of each AE was assessed as mild (transient symptoms, no interference with daily activities), moderate (marked symptoms, moderate interference with daily activities), or severe (considerable interference with daily activities) by the investigator. Serious adverse events are defined as any untoward medical occurrence that at any dose results in death or is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect. The investigator assessed each AE as either related or not related to study treatment. (NCT01429051)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any AE | Any AE reported as related to treatment | Non-serious adverse events | Serious adverse events | Deaths | Severe adverse events | AEs leading to withdrawal | AEs possibly associated with nasal intolerability | AEs with an onset within 30 minutes of first dose | |
| Efficacy Phase | 6 | 4 | 5 | 2 | 1 | 2 | 2 | 0 | 3 |
| Titration Phase | 23 | 14 | 22 | 2 | 2 | 2 | 2 | 2 | 11 |
| Tolerability Phase | 22 | 6 | 17 | 8 | 5 | 7 | 3 | 6 | 5 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, and 30 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID30 was calculated as the time-weighted sum of the PID scores using the following formula: SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30). The minimum and maximum SPID30 scores were -3000 and 3000. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 30 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Sublingual Spray | 640.3 |
| Placebo | 399.6 |
Global evaluation of the study medication was assessed by the participant on a 5-point scale (1=Poor, 2=Fair, 3=Good, 4=Very good, 5=Excellent) at 30 and 60 minutes after each dose of study medication during each breakthrough pain episode. A higher score indicates a better evaluation. (NCT00538850)
Timeframe: 30 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 30 minutes | 60 minutes | |
| Fentanyl Sublingual Spray | 2.8 | 3.1 |
| Placebo | 2.0 | 2.2 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID was calculated as the time-weighted sum of the PID scores using the following formulas: SPID5=(5*PID5), SPID10=(5*PID5)+(5*PID10), SPID15=(5*PID5)+(5*PID10)+(5*PID15), SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30), SPID45=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30)+(15*PID45), SPID60=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30) +(15*PID45) +(15*PID60). The minimum and maximum SPID scores were -500 to 500, -1000 to 1000, -1500 to 1500, -3000 to 3000, -4500 to 4500, and -6000 to 6000, respectively. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| SPID5 | SPID10 | SPID15 | SPID45 | SPID60 | |
| Fentanyl Sublingual Spray | 40.3 | 115.0 | 220.6 | 1122.0 | 1649.0 |
| Placebo | 32.0 | 81.1 | 150.3 | 667.0 | 965.7 |
Pain relief (PAR) was assessed by the participant on a 5-point scale (1=No relief, 2=A little relief, 3=Moderate relief, 4=A lot of relief, 5=Complete relief) at 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. TOTPAR was calculated as the time-weighted sum of the PAR scores at each time point using the following formulas: TOTPAR5=(5*PAR5), TOTPAR10=(5*PAR5)+(5*PAR10), TOTPAR15=(5*PAR5)+(5*PAR10)+(5*PAR15), TOTPAR30=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30), TOTPAR45=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30)+(15*PAR45), TOTPAR60=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30) +(15*PAR45) +(15*PAR60). The minimum and maximum TOTPAR5, TOTPAR10, TOTPAR15, TOTPAR30, TOTPAR45, and TOTPAR60 scores were 5 to 25, 10 to 50, 15 to 75, 30 to 150, 45 to 225, and 60 to 300, respectively. A higher score indicates more pain relief. (NCT00538850)
Timeframe: 5 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| TOTPAR5 | TOTPAR10 | TOTPAR15 | TOTPAR30 | TOTPAR45 | TOTPAR60 | |
| Fentanyl Sublingual Spray | 8.6 | 19.7 | 32.9 | 78.3 | 126.3 | 176.4 |
| Placebo | 7.6 | 16.7 | 27.1 | 61.0 | 95.5 | 131.2 |
43 reviews available for fentanyl and Pain, Breakthrough
| Article | Year |
|---|---|
Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment.
Topics: Analgesics, Opioid; Bibliometrics; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2022 |
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Head and Neck Neoplasms; Humans; Neopl | 2023 |
Is pain part of a systemic syndrome in head and neck cancer?
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Depression; Exercise; Fatigue; Fentanyl; Head an | 2020 |
Breakthrough cancer pain: review and calls to action to improve its management.
Topics: Algorithms; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Communication; Fentanyl; Humans; Onc | 2020 |
Breakthrough cancer pain in 2020.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasm Metastasis; Pain Mana | 2020 |
Fentanyl Formulations in the Management of Pain: An Update.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Breakthrough Pain; Drug Administration Routes; Dr | 2017 |
Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Education, Nursing, Contin | 2017 |
Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Double-Blind Method; Fenta | 2018 |
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.
Topics: Analgesics, Opioid; Breakthrough Pain; Dyspnea; Fentanyl; Humans; Morphine; Neoplasms; Pain Manageme | 2018 |
Treating breakthrough pain in oncology.
Topics: Administration, Buccal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Do | 2018 |
[Opioid switch and change of route of administration in cancer patients treated by morphine].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Drug Substitution; Fentany | 2018 |
The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
Topics: Analgesia; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Measurement; Qua | 2019 |
Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
Topics: Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; D | 2019 |
Fast-acting fentanyl preparations and pain management.
Topics: Analgesics, Opioid; Breakthrough Pain; Drug Dosage Calculations; Fentanyl; Humans; Neoplasms; Pain M | 2013 |
Fentanyl for the treatment of tumor-related breakthrough pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Me | 2013 |
The pharmacoeconomics of breakthrough cancer pain.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakt | 2013 |
[Breakthrough pain and short-acting opioids].
Topics: Administration, Intranasal; Administration, Mucosal; Analgesics, Opioid; Breakthrough Pain; Delayed- | 2013 |
[Management of breakthrough cancer pain].
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Man | 2013 |
Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2013 |
Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chemistry, Pharmaceu | 2012 |
Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Topics: Analgesics, Opioid; Breakthrough Pain; Caregivers; Drug Administration Routes; Family; Fentanyl; Hum | 2014 |
Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain.
Topics: Breakthrough Pain; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms | 2014 |
Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Dose-Respon | 2015 |
WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2015 |
Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Topics: Algorithms; Analgesics, Opioid; Breakthrough Pain; Choice Behavior; Ethnicity; Expert Testimony; Fen | 2016 |
Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Sublingual; Analgesics, Opioid; | 2015 |
Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Disease Management; Fentanyl; Humans; | 2016 |
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Topics: Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain | 2016 |
[Cancer breakthrough pain. Indications for rapidly effective opioids].
Topics: Administration, Intranasal; Administration, Sublingual; Administration, Topical; Aerosols; Analgesic | 2011 |
Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Europe; Fentanyl; Humans; Neoplasms; Pa | 2011 |
Fentanyl for breakthrough pain: a systematic review.
Topics: Acute Pain; Administration, Buccal; Administration, Intranasal; Administration, Mucosal; Administrat | 2011 |
Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Controlled Clinical Trials as Topic; Dr | 2011 |
Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
Topics: Administration, Buccal; Adolescent; Adult; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; | 2012 |
Intranasal fentanyl in the treatment of acute pain--a systematic review.
Topics: Acute Pain; Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Pai | 2012 |
New formulations of fentanyl for acute pain management.
Topics: Acute Pain; Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Analgesics, | 2012 |
Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Fentanyl; Hum | 2012 |
A comprehensive review of rapid-onset opioids for breakthrough pain.
Topics: Breakthrough Pain; Chronic Pain; Drug Administration Routes; Fentanyl; Humans; Patient Satisfaction; | 2012 |
Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Topics: Administration, Intranasal; Aerosols; Analgesics, Opioid; Area Under Curve; Breakthrough Pain; Compu | 2012 |
Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2012 |
The management of wound-related procedural pain (volitional incident pain) in advanced illness.
Topics: Administration, Buccal; Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Cognition | 2013 |
Fentanyl for breakthrough cancer pain: where are we?
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl | 2013 |
Optimal management of breakthrough cancer pain (BCP).
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Nasal Sprays; N | 2013 |
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Causality; Comorbidity; Controlled Clin | 2013 |
39 trials available for fentanyl and Pain, Breakthrough
| Article | Year |
|---|---|
Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial.
Topics: Administration, Sublingual; Adolescent; Adult; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; D | 2023 |
Comparative efficacy of epidural clonidine versus epidural fentanyl for treating breakthrough pain during labor: a randomized double-blind clinical trial.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breakthrough Pai | 2020 |
A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2019 |
Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; C | 2021 |
Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery.
Topics: Administration, Intranasal; Aged; Analgesics, Opioid; Breakthrough Pain; Cardiac Surgical Procedures | 2021 |
Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER).
Topics: Analgesics, Opioid; Breakthrough Pain; Child; Delivery of Health Care; Feasibility Studies; Fentanyl | 2021 |
Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning.
Topics: Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; Fentanyl; Humans; Nasal Sprays; Pectins; Radi | 2016 |
[Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Dose-Respon | 2018 |
The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study.
Topics: Administration, Sublingual; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Breakthrough Pa | 2019 |
Is breakthrough pain better managed by adding programmed intermittent epidural bolus to a background infusion during labor epidural analgesia? A randomized controlled trial.
Topics: Adolescent; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Intravenous; Anesthetic | 2019 |
Programmed intermittent epidural bolus as compared to continuous epidural infusion for the maintenance of labor analgesia: a prospective randomized single-blinded controlled trial.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Breakthrough Pain; Drug Admi | 2019 |
Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthr | 2019 |
An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Breakthrough Pain; Computer Simul | 2013 |
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase
Topics: Administration, Buccal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Breakthrough Pain; C | 2013 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; F | 2013 |
A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Topics: Administration, Buccal; Aged; Analgesics, Opioid; Breakthrough Pain; Double-Blind Method; Female; Fe | 2014 |
A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; F | 2014 |
Fentanyl buccal film. New oral transmucosal form has no advantages in breakthrough pain.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cheek; Fentanyl; Humans; Mouth Mucosa | 2013 |
Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Topics: Administration, Oral; Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Doubl | 2014 |
A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; | 2014 |
Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Dose | 2014 |
Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Chronic Pain; Cross-Over Studies; Dos | 2014 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2015 |
Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Hu | 2015 |
Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; Ethnicity; Fem | 2015 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain | 2015 |
Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Asian People; Breakthrou | 2015 |
Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
Topics: Administration, Buccal; Adult; Affect; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Huma | 2015 |
Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Double-Blind Method; Female; | 2015 |
Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Breakthrough Pain; Drug-Related Side Eff | 2015 |
Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Female; Fentanyl; | 2015 |
Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Double- | 2016 |
A COMPARATIVE STUDY ON THE EFFICACY OF TWO REGIMENS OF SINGLE- SHOT SPINAL BLOCK FOR PAIN RELIEF IN WOMEN PRESENTING IN ESTABLISHED LABOUR.
Topics: Analgesia, Obstetrical; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics, Combined; Anesthetics, | 2013 |
Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, O | 2016 |
Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Topics: Administration, Oral; Analgesics; Breakthrough Pain; Cancer Pain; Cross-Over Studies; Female; Fentan | 2016 |
Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Bone Neopla | 2012 |
Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2012 |
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; | 2012 |
80 other studies available for fentanyl and Pain, Breakthrough
| Article | Year |
|---|---|
Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms; Palliative Care; Pr | 2022 |
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Male; Neoplasms; Pa | 2023 |
Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Multiple Myeloma; Neoplasms; Pain Managemen | 2023 |
Association between breakthrough labor pain, patient-controlled epidural analgesia use, and numeracy: A pilot observational study.
Topics: Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Breakthrough Pain; Female; Fentanyl | 2023 |
Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
Topics: Administration, Buccal; Adolescent; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Canada; Canc | 2020 |
Buccal opioids for breakthrough pain in children with life-limiting conditions receiving end-of-life care.
Topics: Administration, Buccal; Adolescent; Analgesics, Opioid; Breakthrough Pain; Child; Child, Preschool; | 2019 |
A Case of Breakthrough Pain Management with Subcutaneous Fentanyl Administration in a Female Child.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Child; Diagnostic Tests, Routine; Femal | 2020 |
[Comparison of hospital consumption of immediate-release fentanyl: use or abuse?]
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Drug | 2020 |
Pseudo-addiction in cancer patients and rapid-release fentanyl for breakthrough pain: An increasingly common concern.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2021 |
[A Case Report of Impaired Consciousness in a Patient after Receiving the Fourth Dose of Fentanyl Sublingual Tablet].
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Consciousness; Fentanyl; Hu | 2020 |
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakt | 2021 |
[A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mu | 2017 |
Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Topics: Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Cancer Pain | 2017 |
Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
Topics: Administration, Sublingual; Age Factors; Aged; Analgesics, Opioid; Anxiety; Breakthrough Pain; Cance | 2017 |
Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
Topics: Administration, Buccal; Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pai | 2018 |
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Transmucosal fentanyl for severe cancer pain: Nasal mucosa superior to oral mucosa?
Topics: Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mucosa; Nasal Mucosa | 2016 |
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcot | 2017 |
The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
Topics: Administration, Oral; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; Child, | 2017 |
[Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Cancer P | 2017 |
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; Drug The | 2018 |
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Topics: Administration, Buccal; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Bre | 2018 |
Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Canc | 2019 |
[Not all pains are the same: breakthrough pain in cancer patients. A case report].
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Male; Middle Aged; Palliative | 2018 |
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Topics: Administration, Mucosal; Breakthrough Pain; Cancer Pain; Clinical Competence; Contraindications, Dru | 2019 |
[Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.]
Topics: Adenocarcinoma; Administration, Sublingual; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; C | 2019 |
Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study.
Topics: Administration, Mucosal; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Central Nervous S | 2019 |
Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentanyl | 2019 |
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentan | 2019 |
Grading clinical guidelines for the use of transmucosal immediate-release fentanyl products in breakthrough pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Mucous Membrane; Practice Guidelines as Top | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors' reply.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Evidence-based treatment of cancer-related breakthrough pain with opioids.
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Evidence | 2013 |
The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Dose-Respons | 2013 |
[Cancer patient with breakthrough pain].
Topics: Aged; Analgesics, Opioid; Breakthrough Pain; Breast Neoplasms; Disease Progression; Dose-Response Re | 2013 |
[Fentanyl: fast and furious?].
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain, Intractable | 2013 |
The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; M | 2013 |
Treatment of breakthrough cancer pain: to titrate or to proportionate?
Topics: Breakthrough Pain; Female; Fentanyl; Humans; Male | 2013 |
Correspondence (letter to the editor): Lack of precision in colloquial language results in incorrect therapeutic recommendation.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Correspondence (reply): In reply.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl; | 2014 |
The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study.
Topics: Administration, Intranasal; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; M | 2014 |
How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Mucosal; Administration, Subling | 2011 |
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; | 2014 |
Efficacy of rapid-onset oral fentanyl: what does it mean?
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
Trial design for breakthrough pain: is it ethical to have a placebo in a trial? Author reply.
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male | 2014 |
Trial design for breakthrough pain: is it ethical to have a placebo in a trial?
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male | 2014 |
Authors' reply to Davis.
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse.
Topics: Analgesics, Opioid; Breakthrough Pain; Chemoradiotherapy; Coma; Fentanyl; Gastrointestinal Stromal T | 2014 |
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.
Topics: Administration, Inhalation; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Combined Modality Th | 2014 |
A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male | 2014 |
Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Canada; Data Collection; E | 2015 |
Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cohort Studies; Fema | 2015 |
Patients' acceptability of different fentanyl products for breakthrough cancer pain.
Topics: Administration, Mucosal; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Patient Acceptance of Healt | 2014 |
Pharmacologic management of adult breakthrough cancer pain.
Topics: Adult; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Sufentanil | 2014 |
Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chronic Pain; Cohort | 2015 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pect | 2015 |
Use of oral formulations of fentanyl for breakthrough cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; Humans | 2015 |
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
Topics: Administration, Buccal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammator | 2016 |
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Fem | 2016 |
Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Sublingual; Analgesics, Opioid; | 2015 |
Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; F | 2015 |
The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Autonomic Agents; Breakthrough Pain; Cancer Pa | 2016 |
Re: The Influence of Low Salivary Flow Rates on Sublingual Fentanyl Absorption for Breakthrough Cancer Pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2016 |
Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Expert Testimony; Fentanyl; Humans; Neoplasms | 2016 |
Breakthrough pain: just pain?
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain Measurement | 2016 |
The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; M | 2017 |
Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antineoplastic Agents; Breakthrough Pain; Cispla | 2017 |
Opioid manufacturer bribed doctors to prescribe fentanyl inappropriately, US says.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Crime; Drug Industry; Fentanyl; Humans; Malpract | 2016 |
Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Femal | 2018 |
Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Causality; Chr | 2011 |
Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Absorption; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; | 2012 |
Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationsh | 2011 |
Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Topics: Adult; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; Fatal Outcome; Female; Fentanyl; Human | 2011 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male; Nasal Sprays; Neoplasms; Trea | 2012 |
Patient satisfaction with intranasal fentanyl for breakthrough pain.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Female; | 2012 |
[Breakthrough pain in a patient with bronchial carcinoma. Oral morphine hardly possible - what can help?].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Carcinoma, B | 2012 |
Are there cost benefits to fentanyl for breakthrough pain?
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; | 2012 |
[Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
Topics: Advertising; Analgesics, Opioid; Breakthrough Pain; Drug Industry; Drug Tolerance; Education; Fentan | 2013 |